Patient description: The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed: Post-void residual: 71 mL Prostate volume (TRUS): 63 mL Prostate-specific antigen (PSA) level: 3.5 ng/mL His recent blood chemistry (3 days ago) was normal: Hgb: 13.6 g/dl WBC: 133000 /mm3 Plt: 370000 /ml PT: 12 second PTT: 34 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Acute Lymphoblastic Leukemia, Adult Ph+ ALL Newly Diagnosed Patients with newly diagnosed, previously untreated, Ph-positive [either t(9;22) and/or BCR-ABL positive] B-precursor acute lymphoblastic leukemia Age 18-65 years Eligible to intensive chemotherapy, due to general health status ECOG (Eastern Cooperative Oncology Group) performance status ≤2 Absence of significant liver disease, as defined by the following total serum bilirubin ≤1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome, alanine aminotransferase (ALT) ≤2.5 × ULN or ≤5 x ULN if leukemic involvement of the liver is present, and aspartate aminotransferase (AST) ≤2.5 × ULN or ≤5 x ULN if leukemic involvement of the liver is present Adequate pancreatic function as defined by serum amylase and lipase ≤1.5 × ULN Diagnostic sample of bone marrow (or peripheral blood with >50% of blasts) available for central MRD assessment Subject has provided written informed consent prior to any screening procedure  Lymphoid blast crisis of chronic myelocytic leukemia (CML) Active serious infection not controlled by oral or intravenous antibiotics Active known hepatitis B virus (HBV) or hepatitis C virus (HCV) or positive HIV serology History of acute pancreatitis within 1 year of study or history of chronic pancreatitis Uncontrolled hypertriglyceridemia (triglycerides > 5.1 µmol/L) Clinically significant, uncontrolled or active cardiovascular disease, specifically including, but not restricted to: any history of myocardial infarction, stroke, or revascularization; unstable angina or transient ischemic attack within 6 months prior to enrolment; congestive heart failure within 6 months prior to enrolment or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards; history of clinically significant (as determined by the treating physician) atrial arrhythmia; any history of ventricular arrhythmia; any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism Uncontrolled hypertension (diastolic blood pressure >90 mmHg; systolic >140 mmHg). Patients with hypertension should be under treatment on study entry to effect blood pressure control Creatinine levels > 160 µmol/L or estimated creatinine clearance of < 50 mL/min GI disease and/or major GI surgery that may significantly alter the absorption of study drug Hypersensitivity to the active substance or to any of the excipients, especially galactose intolerance